PFO
CRBP icon

Pathstone Family Office’s Corbus Pharmaceuticals CRBP Stock Holding History

Pathstone Family Office’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-9
Closed -$1K – 761
2020
Q1 		$1K Buy
+9
New +$1.52K ﹤0.01% 711

Other funds holding CRBP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pathstone Family Office's CRBP Position: Q2 2020 in Review

Pathstone Family Office sold out of Corbus Pharmaceuticals (CRBP) in Q2 2020, closing a stake of 9 shares — an estimated $1K sold.

Pathstone Family Office first reported a position in CRBP in Q1 2020 and held it in 1 quarter. The position peaked at $1K in Q1 2020. 140 funds tracked by Wall St. Rank hold CRBP as of Q2 2020.

  • Pathstone Family Office reported no remaining Corbus Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Pathstone Family Office sold 9 Corbus Pharmaceuticals shares in Q2 2020, an estimated $1K.
  • Pathstone Family Office first reported a position in Corbus Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • Pathstone Family Office's Corbus Pharmaceuticals position peaked at $1K in Q1 2020.
  • 140 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2020.

Based on Pathstone Family Office's 13F filing for Q2 2020, filed 14 Aug 2020.